DelveInsight’s “Meconium Aspiration Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Meconium Aspiration Syndrome, historical and forecasted epidemiology as well as the Meconium Aspiration Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Meconium Aspiration Syndrome Overview
Meconium aspiration syndrome occurs when a newborn breathes a mixture of meconium and amniotic fluid into the lungs around the time of delivery. Meconium aspiration syndrome, a leading cause of severe illness and death in the newborn, occurs in about 5 percent to 10 percent of births.
Meconium Aspiration Syndrome Epidemiology Insights
In the industrialized world, meconium in the amniotic fluid can be detected in 8-25% of all births after 34 weeks gestation. Historically, approximately 10% of newborns born through meconium-stained amniotic fluid developed meconium aspiration syndrome.
Higher risk of MASINT was noted at advanced gestation, with 34% of cases born beyond 40 weeks, compared with 16% of infants without MAS. Fetal distress requiring obstetric intervention was noted in 51% of cases, and 42% were delivered by cesarean section.
Click here to learn more about the Meconium Aspiration Syndrome Market Landscape
The Report Covers the Meconium Aspiration Syndrome Epidemiology Segmented by:
Total Meconium Aspiration Syndrome incident cases
Total Meconium Aspiration Syndrome prevalent cases
Total Meconium Aspiration Syndrome treatment cases
Total Meconium Aspiration Syndrome diagnostic cases
Meconium Aspiration Syndrome Market Outlook
The Meconium Aspiration Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current and forecasted Meconium Aspiration Syndrome market trends by analyzing the impact of current Meconium Aspiration Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Meconium Aspiration Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Meconium Aspiration Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.According to DelveInsight, the Meconium Aspiration Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Meconium Aspiration Syndrome Market
Fervent Pharmaceuticals
Astellas Pharmaceuticals
Bayer
Pfizer
Novartis
Takeda
GlaxsoSmith Kline
And many others
Meconium Aspiration Syndrome Therapies Covered and Analyzed in the Report:
FP101
Fezolinetant
Erenumab
MF101
Cyproterone Acetate
PD-0299685
Gabapentin
Learn more about the Key Companies and Emerging Therapies in the Meconium Aspiration Syndrome Market
Table of Contents
Key Insights
Meconium Aspiration Syndrome Introduction
Executive Summary of Meconium Aspiration Syndrome
Disease Background and Overview
Epidemiology and patient population
Meconium Aspiration Syndrome Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Meconium Aspiration Syndrome Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services